Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy
- Sponsor
- Samsung Medical Center
- Study ID
- NCT02072408
- Phase
- PHASE4
- Status
- Completed
Conditions
- Polypoidal Choroidal Vasculopathy Without Active Polyp
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- aflibercept — DRUG1. Three monthly intravitreal aflibercept (2mg) injections 2. Five bimonthly intravitreal aflibercept (2mg) injections 3. Rescue treatment: Verteporfin photodynamic therapy * Loss of five ETDRS letters or one Snellen line of vision from baseline * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection * Presence of active polyp on indocyanine green angiography
Study Details
The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.
Key Dates
- Start date
- Feb 28, 2014
- Status verified
- Feb 2014
- Primary completion
- Nov 2, 2017
- Completion
- Nov 2, 2017
Study Design
- Enrollment
- 46 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: polypoidal choroidal vasculopathy without polyp
Primary Outcome Measure
Change of best-corrected visual acuity (ETDRS letters) [ Time Frame: 1 year ]